Franklin Biolabs CEO Selected as a 2026 Women of Influence by the Philadelphia Business Journal
Learn more

AAV Vector Aggregation Analysis for IND-Enabling Programs

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

AAV Vector Aggregation Analysis for IND-Enabling Programs

CELL & GENE | RNA | BIOLOGICS

Proven Intelligence in Vector Integrity for Preclinical Success.

A female scientist in a lab coat analyzes complex biological data, including cellular imagery and DNA models, on a computer screen.

Frequently Asked Questions

Why is AAV vector aggregation a primary focus in IND-enabling toxicology studies?

AAV vector aggregation is a key quality attribute that directly impacts the safety and efficacy profile of a therapeutic candidate. Aggregates can trigger unintended immune responses, alter biodistribution, and reduce transduction efficiency, confounding the results of IND-enabling toxicology studies. Regulatory bodies require robust characterization to ensure the material administered in pivotal nonclinical studies is representative of the clinical product.

What analytical methods are used to assess AAV aggregation under GxP conditions?

A multi-attribute approach is necessary. Methods typically include size-exclusion chromatography with multi-angle light scattering (SEC-MALS), dynamic light scattering (DLS), analytical ultracentrifugation (AUC), and particle analysis by micro-flow imaging (MFI). These assays are developed and qualified in a phase-appropriate manner within GxP-compliant environments to provide definitive data on the monomeric purity and stability of the vector.

How does early aggregation analysis impact the 18-24 month timeline to IND?

Proactively identifying and controlling aggregation during process development prevents costly delays. A stable, well-characterized vector formulation avoids failed toxicology batches, inconclusive safety data, and regulatory questions that can extend program timelines. Integrating this analysis early ensures a smoother path through preclinical development, supporting an accelerated 18-24 month timeline to a successful IND submission.

The biophysical integrity of an adeno-associated virus (AAV) vector is foundational to its performance in vivo. Vector aggregation, the formation of non-specific multimers, presents a significant risk to preclinical programs by potentially altering immunogenicity and compromising transduction efficiency. Integrating aggregation analysis early is a core component of a de-risked IND-enabling strategy, ensuring biophysical integrity is established well before pivotal studies.

Regulatory expectations, harmonized under ICH guidelines, demand a clear understanding of the product administered in pivotal safety and toxicology studies. Data packages must demonstrate that the vector is predominantly monomeric and that aggregation is controlled within defined specifications. Failure to provide this evidence can result in significant delays and requests for additional characterization studies.

A senior scientist with grey hair is mentoring a diverse group of younger scientists or students in a laboratory setting.

A Multi-Attribute Analytical Strategy

A single analytical method is insufficient to fully characterize AAV aggregation. A robust analytical control strategy for preclinical vectors leverages an orthogonal set of methods to build a comprehensive profile of the material.

  • Size-Exclusion Chromatography (SEC-MALS): Quantifies the proportion of monomer, dimer, and higher-order oligomers.

  • Dynamic Light Scattering (DLS): Provides data on the hydrodynamic radius and polydispersity of the vector population.

  • Analytical Ultracentrifugation (AUC): Offers high-resolution separation of species based on sedimentation velocity.

  • Micro-Flow Imaging (MFI): Characterizes sub-visible particles that may not be detected by other methods.

Developing and qualifying these assays under GxP conditions ensures data integrity for global regulatory submissions, including IND and IMPD filings.

Translational Impact of Vector Quality

The predictability of clinical outcomes from preclinical data depends heavily on vector quality. A well-characterized AAV8 vector, for instance, demonstrated sustained correction of disease biomarkers in a preclinical model of OTC deficiency, a result contingent on a high-purity vector preparation reaching its target tissue effectively (PMID: 22133298).

This requirement for vector integrity is amplified with the use of novel, engineered capsids. While these vectors can achieve highly specific tissue targeting, their unique biophysical properties may present new aggregation challenges that must be thoroughly investigated to ensure their performance is not compromised (PMID: 37199615).

Our scientific team’s track record, which includes a 100% successful IND rate since 2019, is built on this rigorous approach to vector analytics. While Franklin Biolabs formally launched in 2024, this success rate reflects the deep institutional knowledge of our core scientific leadership and principal scientists. This continuity of expertise ensures that every vector is built on a foundation of proven science. A biotech partner highlighted our team’s “Vast knowledge in all aspects of vector production and analytics,” which is foundational to navigating complex characterization challenges. Learn more about our integrated approach at Vector | CMC | Analytics Services.

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities